ホーム > 製品 > 抗体 > バイオシミラー

Research Grade Bococizumab (HV275046)

データシート製品共有情報コピー

Research Grade Bococizumab

Research Grade Bococizumab

Research Grade Bococizumab

Research Grade Bococizumab

Research Grade Bococizumab

Research Grade Bococizumab

価格(USD): $

スペック:

100ug
1mg

数量:

お問い合わせ

概要
イメージ
参考文献
データシート

概要

カタログ番号	HV275046
説明	Bococizumab (HV275046) is a research-grade recombinant antibody targeting Proprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
種反応性	Human
アプリケーション	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種	Humanized
アイソタイプ	IgG2-kappa
発現システム	Mammalian Cells
クローン性	Monoclonal
ターゲット	Proprotein convertase subtilisin/kexin type 9, Subtilisin/kexin-like protease PC9, NARC-1, PC9, Proprotein convertase 9, Neural apoptosis-regulated convertase 1, NARC1, PCSK9
エンドトキシンレベル	Please contact the lab for this information.
純度	>95% purity as determined by SDS-PAGE.
精製	Protein A/G purified from cell culture supernatant.
アクセッション番号	Q8NBP7
形態	Liquid
保存バッファー	0.01M PBS, pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。
安定性と保存	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
別名	PF-04950615, RN-316, 1407495-02-6
背景	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a ~74 kDa protein. Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. PCSK9 is the therapeutic target of evolocumab (Repatha). 1. Poirier, S. et al. (2008) The Journal of biological chemistry 283, 2363-72. PMID: 18039658 2. Nassoury, N. et al. (2007) Traffic (Copenhagen, Denmark) 8, 718-32. PMID: 17461796 3. Fan, D. et al. (2008) Biochemistry 47, 1631-9. PMID: 18197702 4. Mayer, G. et al. (2008) The Journal of biological chemistry 283, 31791-801. PMID: 18799458 5. Chen, Y. et al. (2011) Biochemical and biophysical research communications 415, 515-8. PMID: 22074827 6. Jonas, MC. et al. (2008) EMBO reports 9, 916-22. PMID: 18660751
注意事項	For research use only. Not suitable for clinical or therapeutic use.

イメージ

SDS-PAGE

SDS-PAGE for Research Grade Bococizumab
Bioactivity

SEC-HPLC detection for Research Grade Bococizumab.
Bioactivity

Detects Human PCSK9 in indirect ELISAs.
Immobilized Human PCSK9, His Tag (Catalog No: HV275011) at 1 μg/mL (100 μL/well) on an Anti-His antibody (Catalog No: YP205015) Coated plate can bind Human PCSK9 Mab

参考文献

HV275046-SDS-PAGE-1.jpg

データシート

Research Grade Bococizumab.pdf

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

=

Concentration

×

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

×

V₁ (Stock Vol.)

=

Working Solution

C₂ (Working Conc.)

×

V₂ (Working Vol.)

レコメンデーション

お問い合わせカスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト

Research Grade Bococizumab